[go: up one dir, main page]

WO2007136615A3 - Combination cancer therapy - Google Patents

Combination cancer therapy Download PDF

Info

Publication number
WO2007136615A3
WO2007136615A3 PCT/US2007/011595 US2007011595W WO2007136615A3 WO 2007136615 A3 WO2007136615 A3 WO 2007136615A3 US 2007011595 W US2007011595 W US 2007011595W WO 2007136615 A3 WO2007136615 A3 WO 2007136615A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer therapy
amount
combination cancer
subject
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/011595
Other languages
French (fr)
Other versions
WO2007136615A2 (en
Inventor
Andrew M Bloecher
Steven J Freedman
Matthew W Harding
Shinichi Hasako
Russell R Hoover
Toshiyasu Shimomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Vertex Pharmaceuticals Inc
Merck and Co Inc
Original Assignee
Banyu Phamaceutical Co Ltd
Vertex Pharmaceuticals Inc
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Phamaceutical Co Ltd, Vertex Pharmaceuticals Inc, Merck and Co Inc filed Critical Banyu Phamaceutical Co Ltd
Publication of WO2007136615A2 publication Critical patent/WO2007136615A2/en
Publication of WO2007136615A3 publication Critical patent/WO2007136615A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of an Aurora kinase inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the Aurora kinase inhibitor and the anti-cancer agent may be additive or synergistic.
PCT/US2007/011595 2006-05-16 2007-05-15 Combination cancer therapy Ceased WO2007136615A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80079506P 2006-05-16 2006-05-16
US60/800,795 2006-05-16

Publications (2)

Publication Number Publication Date
WO2007136615A2 WO2007136615A2 (en) 2007-11-29
WO2007136615A3 true WO2007136615A3 (en) 2008-07-24

Family

ID=38723796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011595 Ceased WO2007136615A2 (en) 2006-05-16 2007-05-15 Combination cancer therapy

Country Status (1)

Country Link
WO (1) WO2007136615A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4638148B2 (en) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Treatment of neurodegenerative diseases and brain cancer
AU2007277226A1 (en) * 2006-07-26 2008-01-31 Merck & Co., Inc. A novel lactic acid formulation of MK-0457 useful for the treatment of cancer
CN102105147B (en) * 2008-07-24 2013-07-03 内尔维阿诺医学科学有限公司 Therapeutic combination comprising an AURORA kinase inhibitor and an antineoplastic agent
WO2011131636A1 (en) 2010-04-19 2011-10-27 Institut Curie Combined treatment of cancer with benzo[e]pyridoindoles and dna-damaging agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222190A1 (en) * 2004-03-30 2005-10-06 Curd John G 1,4-bis-N-oxide azaanthracenediones and the use thereof
US20060178435A1 (en) * 2004-11-02 2006-08-10 The Regents Of The University Of Michigan Apogossypolone and the uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222190A1 (en) * 2004-03-30 2005-10-06 Curd John G 1,4-bis-N-oxide azaanthracenediones and the use thereof
US20060178435A1 (en) * 2004-11-02 2006-08-10 The Regents Of The University Of Michigan Apogossypolone and the uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROXTERMAN ET AL.: "Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations", DRUG RESISTANCE UPDATES, vol. 8, 2005, pages 183 - 197, XP005112189 *
GARBER K.: "Divide and Conquer: New Generation of Drugs Targets Mitosis", JOURNAL OF NATIONAL CANCER INSTITUTE, vol. 97, no. 12, 15 June 2005 (2005-06-15), pages 874 - 876 *

Also Published As

Publication number Publication date
WO2007136615A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2005023179A3 (en) Combination methods of treating cancer
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
WO2004108157A3 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2009064444A9 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
UA103614C2 (en) Medicinal composition for treating hepatic cancer which comprises a kinase inhibitor. combined with glypican 3 antibody
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2009074827A3 (en) Combination comprising a mek inhibitor and an aurora kinase inhibitor
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2010124283A3 (en) Methods and compositions relating to hematologic malignancies
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008077062A3 (en) Suppression of stat3 reactivation after src kinase inhibition to treat cancer
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007109093A3 (en) Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2007136615A3 (en) Combination cancer therapy
WO2009073139A3 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
WO2009088992A3 (en) Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
WO2010005585A3 (en) 4-aminoquinazoline prodrugs
MX2008016520A (en) Use of wnt5a for inhibiting scarring.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07756260

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07756260

Country of ref document: EP

Kind code of ref document: A2